Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society 68th Annual Scientific Meeting
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2026 Annual Meeting
SAGA Metals Drills 495.6 m at 37.86% Fe2O3, 5.51% TiO2, 0.273% V2O5 Including 68.2 m at 52.95% Fe2O3, 8.57% TiO2, 0.381% V2O5 at Radar Critical Minerals Project in Labrador
SAGA Metals Drills 495.6 m at 37.86% Fe2O3, 5.51% TiO2, 0.273% V2O5 Including 68.2 m at 52.95% Fe2O3, 8.57% TiO2, 0.381% V2O5 at Radar Critical Minerals Project in Labrador
Metalsource Mining Launches Major Step Out Program With 1.1 km Northern Target to Test Broader Scale of Silver Hill
Skyharbour Commences Drilling at the Getty East Uranium Joint Venture with Partner Denison Mines at the Russell Lake Project Area
